Guaifenesin/hydrocodone/pseudoephedrine - Mission Pharmacal

Drug Profile

Guaifenesin/hydrocodone/pseudoephedrine - Mission Pharmacal

Alternative Names: Guaifenesin/hydrocodone bitartrate/pseudoephedrine hydrochloride - Mission Pharmacal; HycofenixTM

Latest Information Update: 04 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mission Pharmacal
  • Class Amines; Antitussives; Expectorants; Morphinans; Opioid analgesics
  • Mechanism of Action Alpha adrenergic receptor agonists; Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cough; Nasal congestion

Most Recent Events

  • 28 Nov 2015 Mission has patent protection for Hycofenix™ in USA
  • 19 Nov 2015 Launched for Cough in USA (PO) before November 2015
  • 19 Nov 2015 Launched for Nasal congestion in USA (PO) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top